STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sandoz agreed to pay $400 million over seven years beginning in 2027 to resolve all remaining state claims in three pending cases, plus roughly $50 million to states that settled earlier
- Sandoz will pay an additional $28.5 million to resolve remaining class-action litigation brought by indirect resellers, bringing total settlement value to $478.5 million
- Sandoz denied any wrongdoing as part of the agreement, which resolves allegations of a widespread conspiracy to artificially inflate and manipulate generic drug prices
- Glenmark Pharmaceuticals, Lannett, Bausch, Apotex, and Heritage Pharmaceuticals previously settled related lawsuits for a combined $98 million, framing Sandoz's payout as the largest to date in the multi-year generic drug price-fixing fight
- The settlement targets two distinct plaintiff groups — U.S. state attorneys general and indirect resellers — with separate payment structures for each track
Why it matters: Sandoz's $478.5 million settlement is roughly five times the combined $98 million paid by five other generic-drug makers in the same litigation wave, marking it as the biggest individual payout yet in the long-running state-led price-fixing cases. The seven-year, 2027-start payment schedule gives Sandoz time before costs hit, while consumers and state health budgets absorb the upstream cost of inflated generic prices the suit alleges persisted for years.
